Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PPM1B | O75688 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9806822 | 0.98 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15443062 | 0.98 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11807272 | 0.98 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11591761 | 0.98 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1441063 | 0.98 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18888 | 0.98 | ALDH1A1 (0.71) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4282507 | 0.96 | ALDH1A1 (0.69) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29427 | 0.95 | — | — | |
| Bicarbonate SCHEMBL9233185 | 0.94 | ALDH1A1 (0.67) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| Bromide SCHEMBL27697419 | 0.92 | ALDH1A1 (0.65) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018088-A1 | SEPARATION AND PURIFICATION METHOD OF 2-NITROETHANOL | FUDAN UNIVERSITY (CN) | 2024-01-18 | — | — | US | claimed |
| CN-111164077-B | Herbicidal 3-phenyl-5-trifluoromethyl isoxazoline-5-carboxamides of cyclopentylcarboxylic acids and esters thereof | 拜耳公司 | 2023-12-19 | — | — | CN | claimed |
| CN-116601149-A | Aminoquinazoline derivatives as P2X3 inhibitors | 奇斯药制品公司 | 2023-08-15 | — | — | CN | claimed |
| CN-116410093-A | Separation and purification method of 2-nitroethanol | 复旦大学 | 2023-07-11 | — | — | CN | claimed |
| CN-112358482-A | [1,2,4] triazole derivative and application thereof in preparation of medicines for treating neurodegenerative diseases and premature ovarian failure | 李奇峰 | 2021-02-12 | — | — | CN | claimed |
| CN-109444292-A | A kind of HPLC method separating (R)-methychlothiazide and (S)-methychlothiazide | 南京盖斯夫医药科技有限公司 | 2019-03-08 | — | — | CN | claimed |
| CN-109342612-A | A kind of HPLC method separating (R)-bendroflumethiazide and (S)-bendroflumethiazide | 南京盖斯夫医药科技有限公司 | 2019-02-15 | — | — | CN | claimed |
| CN-108929246-A | A kind of method that solid state process prepares hydroximic acid derivative | 湖南中医药大学 | 2018-12-04 | — | — | CN | claimed |
| CN-105925246-A | Electricity generated acid produced by blending substances with changeable oxidation state and electrolyte and applications thereof | 吉林大学 | 2016-09-07 | — | — | CN | claimed |
| CN-103539670-B | A kind of preparation method of 1-[(4-chlorphenyl) methyl]-2-oxo-cyclopentane formic acid esters | 上海华谊（集团）公司 | 2016-08-17 | — | — | CN | claimed |
| CN-1414848-A | Prevention of plaque rupture by ACAT inhibitors | WARNER LAMBERT CO (US) | 2003-04-30 | — | — | CN | claimed |
| US-20030069204-A1 | Strain of streptomyces | SANKYO COMPANY LIMITED (JP) | 2003-04-10 | — | — | US | claimed |
| US-6472384-B1 | Antimicrobial compounds | SANKYO COMPANY, LIMITED (JP) | 2002-10-29 | — | — | US | claimed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| EP-1095947-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | Sankyo Company Limited (JP) | 2001-05-02 | — | — | EP | claimed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-4308380-A | 2-Lower alkyl-2 or 3-cephem-4-carboxylic acid derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-12-29 | — | — | US | claimed |
| US-4267340-A | BACTERICIDES; SYNTHESIS OF PENICILLINS AND CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-05-12 | — | — | US | claimed |
| US-4009159-A | PENICILLINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-02-22 | — | — | US | claimed |
| US-3993646-A | Process for the ring expansion of penicillins to cephalosporin compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-11-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069204-A1 | Strain of streptomyces | O60361, CYP8B1, MRPS34 | ALDH1A1 858/4885MAPT 4871/4885MEN1 2623/4885 |
| US-20240018088-A1 | SEPARATION AND PURIFICATION METHOD OF 2-NITROETHANOL | NUCB2, DNPH1, ECE2 | ALDH1A1 1574/4885MAPT 1299/4885MEN1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.